Saturday 17 October 2026
Export PULM’s income statement to Excel — free account
Pulmatrix, Inc.
PULM Healthcare Biotechnology
Pulmatrix, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.8 million, up 6.96% from fiscal 2023. In the quarter to June 2026, revenue fell 99.9%, EPS grew 31.0% and free cash flow grew 41.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
1.36
0.05
−3.55%
Follow PULM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (111.99%) | (92.48%) | (80.93%) | (79.47%) |
+8 more TTM periods Free account |
|
| (85.74%) | (72.14%) | (73.31%) | (75.43%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(158.00%) | (126.28%) | (135.84%) | (131.70%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.07) | (1.28) | (1.49) | (1.64) | |
Free Cash Flow |
(3.91) | (4.69) | (5.43) | (5.99) | |
| Other line items | |||||
Cash ROIC |
(72.07%) | (61.55%) | (68.79%) | (62.85%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.97 | 1.04 | 1.05 | 0.96 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.07) | (1.28) | (1.49) | (1.64) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates